To Boost Or Not To Boost? Pfizer, FDA, And The COVID Vaccine Communication Challenge
Pfizer’s bid for third dose appears to get pushback from the US government, but reticence about the booster may reflect PR considerations more than any fundamental concern about the vaccine.
You may also be interested in...
ACIP will discuss possible boosters for immunocompromised people next week. Pfizer’s head of vaccine R&D and BioNTech co-founder and CEO discuss whether neutralizing antibodies are necessary for protection against SARS-CoV-2, indication in children, and the low and high points of their collaboration at Stat summit.
US position remains that boosters are not needed yet, but CBER Director Peter Marks says regulators are discussing how to harmonize applications for booster shots.
COVID-19 Vaccines: Declining Antibody Levels, Breakthrough Infections Could Spur Booster Recommendations
Although data to support use of booster doses currently are lacking, members of the US CDC's Advisory Committee on Immunization Practices suggest potential triggers for recommending revaccination after the primary series.